Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models.

Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models.

Rituximab, a monoclonal antibody targeting CD20 on B cells, is currently used to treat many subtypes of B cell lymphomas. However, treatment is not curative and response rates are variable. Recombinant interleukin-21 (rIL-21) is a cytokine that enhances immune effector function and affects both prim...

Full description

Bibliographic Details
Main Authors: Cecile M Krejsa, Rick D Holly, Mark Heipel, Ken M Bannink, Rebecca Johnson, Richard Roque, Jane Heffernan, Julie Hill, Lay Chin, Felecia Wagener, Faith Shiota, Katherine Henderson, Pallavur V Sivakumar, Hong-Ping Ren, Fariba Barahmand-Pour, Don Foster, Chris Clegg, Wayne Kindsvogel, Rafael Ponce, Steven D Hughes, Kim Waggie
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3692496?pdf=render

Internet

http://europepmc.org/articles/PMC3692496?pdf=render

Similar Items